Literature DB >> 3355763

In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.

G J Peters1, J van Dijk, E Laurensse, C J van Groeningen, J Lankelma, A Leyva, J C Nadal, H M Pinedo.   

Abstract

The effect of delayed uridine administration on the in vitro growth inhibitory effects of 5-fluorouracil (5FU) and on the in vivo antitumour activity and toxicity was studied. In vitro growth inhibition of the human intestinal cell lines WiDr and Intestine 407 by 3 microM 5FU could be reversed by 1.0 mM uridine; the effect was more pronounced with WiDr cells. At 0.1 mM uridine an intermediate effect was observed. Inhibition of colony formation in both cell lines could also be reversed by delayed administration of uridine at 0.1 and 1 mM. Incorporation of 5FU into RNA of WiDr cells did not proceed after addition of uridine, in contrast to Intestine 407 cells. In these cells only a partial inhibition was observed. In vivo we studied the effect of uridine on two colon carcinoma tumour lines, the 5FU sensitive Colon 38 and the relatively resistant Colon 26. 5FU was administered i.p. in a weekly schedule. With Colon 26 delayed administration of uridine (3500 mg kg-1) at 2 and 20 h after 5FU enabled us to increase the 5FU dose from 100 to 250 300mg kg-1. The combination of high-dose 5FU and uridine resulted both in a superior antitumour effect and an increase in life span. In the 5FU sensitive Colon 38 we determined whether the sensitivity to 5FU was affected by uridine. Mice were treated at the non-lethal dose of 100 mg kg-1 which inhibited tumour growth almost completely. Delayed administration of uridine did not significantly affect the antitumour effect. In non-tumour bearing mice we studied the time course of the reversal of the haematological toxicity of 5FU. The effective dose of 100 mg kg-1 induced a significant decrease in leukocytes; in combination with delayed uridine the leukopenia was less severe and recovered more rapidly. 5FU also induced a decrease in haematocrit, which could be prevented by delayed administration of uridine. In conclusion, in cell culture the reversal of 5FU cytotoxicity could be achieved at a low concentration of 0.1 mM uridine, the extent of the reversal might be related to the 5FU incorporation into RNA. In vivo the relatively resistant tumour Colon 26 could be treated with a higher dose of 5FU in the presence of uridine. The sensitivity to 5FU of the sensitive Colon 38 was not affected by delayed administration of uridine, while the haematological toxicity of 5FU was less. So, delayed administration of uridine after 5FU resulted in an improved therapeutic effect in both a relatively resistant and sensitive tumour.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355763      PMCID: PMC2246507          DOI: 10.1038/bjc.1988.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine.

Authors:  J A Houghton; P J Houghton; R S Wooten
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

2.  Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas.

Authors:  T H Corbett; D P Griswold; B J Roberts; J C Peckham; F M Schabel
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

3.  Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells.

Authors:  J M Karle; L W Anderson; R L Cysyk
Journal:  J Biol Chem       Date:  1984-01-10       Impact factor: 5.157

4.  Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.

Authors:  P Klubes; I Cerna
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

5.  The effects of 5-fluorouracil on hematopoiesis: studies of murine megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels.

Authors:  A M Yeager; J Levin; F C Levin
Journal:  Exp Hematol       Date:  1983-11       Impact factor: 3.084

6.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

7.  Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice.

Authors:  D S Martin; R L Stolfi; R C Sawyer; S Spiegelman; C W Young
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

9.  Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.

Authors:  A Leyva; C J van Groeningen; I Kraal; H Gall; G J Peters; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Uridine-induced hyperthermia in the rabbit.

Authors:  J C Cradock; B R Vishnuvajjala; T F Chin; H D Hochstein; S K Ackerman
Journal:  J Pharm Pharmacol       Date:  1986-03       Impact factor: 3.765

View more
  10 in total

1.  Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.

Authors:  Martina Bajzikova; Jaromira Kovarova; Ana R Coelho; Stepana Boukalova; Sehyun Oh; Katerina Rohlenova; David Svec; Sona Hubackova; Berwini Endaya; Kristyna Judasova; Ayenachew Bezawork-Geleta; Katarina Kluckova; Laurent Chatre; Renata Zobalova; Anna Novakova; Katerina Vanova; Zuzana Ezrova; Ghassan J Maghzal; Silvia Magalhaes Novais; Marie Olsinova; Linda Krobova; Yong Jin An; Eliska Davidova; Zuzana Nahacka; Margarita Sobol; Teresa Cunha-Oliveira; Cristian Sandoval-Acuña; Hynek Strnad; Tongchuan Zhang; Thanh Huynh; Teresa L Serafim; Pavel Hozak; Vilma A Sardao; Werner J H Koopman; Miria Ricchetti; Paulo J Oliveira; Frantisek Kolar; Mikael Kubista; Jaroslav Truksa; Katerina Dvorakova-Hortova; Karel Pacak; Robert Gurlich; Roland Stocker; Yaoqi Zhou; Michael V Berridge; Sunghyouk Park; Lanfeng Dong; Jakub Rohlena; Jiri Neuzil
Journal:  Cell Metab       Date:  2018-11-15       Impact factor: 27.287

2.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

Authors:  J A van Laar; C L van der Wilt; M Treskes; W J van der Vijgh; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.

Authors:  J P Sommadossi; E M Cretton; L B Kidd; H M McClure; D C Anderson; M H el Kouni
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.

Authors:  J Kralovanszky; N Prajda; S Kerpel-Fronius; T Bagrij; E Kiss; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

8.  Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.

Authors:  Anthony Dominijanni; William H Gmeiner
Journal:  Cancer Drug Resist       Date:  2018-03-19

9.  Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.

Authors:  Wen Wee Ma; Muhammad Wasif Saif; Bassel F El-Rayes; Marwan G Fakih; Thomas H Cartwright; James A Posey; Thomas R King; Reid W von Borstel; Michael K Bamat
Journal:  Cancer       Date:  2016-09-13       Impact factor: 6.860

10.  An Oral Fluorouracil Prodrug, Capecitabine, Mitigates a Gram-Positive Systemic Infection in Mice.

Authors:  Pamela A Harvey; Corrella S Detweiler; Jack R McLeod
Journal:  Microbiol Spectr       Date:  2021-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.